The Inflation Reduction Act of 2022 (the “IRA”) includes several provisions that will impact our business to varying degrees, including provisions that allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, among others.
All entries for: Bicara Therapeutics Inc.
August 12, 2025
Bicara Therapeutics Inc.
Negative Outlook
Cambridge, Massachusetts
1-50 employees
Disease Area: Oncology
Drug Type: Biologic